Table 6.

Summary of most relevant clinical studies on T-PLL

Regimen	Trial	Disease status	n	ORR, %	CR, %	PR, %	PFS, mo	OSa, mo	Reference
Pentostatin	Single center, retrospective	Pretreated	56	45	9	36	6	9	55
Alemtuzumab, IV	Single center, retrospective	Pretreated	15	73	60	13	6	8	46
Alemtuzumab, IV	Multicenter, prospective	Pretreated	39	76	60	16	7	10	47
Alemtuzumab, IV	Multicenter, retrospective	Untreated	4	75	75	0	4.5	7.5	52
		Pretreated	72	50	37.5	12.5
Pentostatin + alemtuzumab, IV	Single center, prospective	Pretreated	13	69	62	8	7.8	10.2	56
Alemtuzumab, IV	Single center, prospective	Untreated	32	91	81	10	(67%) 12 mo	(37%) 48 mo	4
Alemtuzumab, sc		Untreated	9	33	33	0	(67%) 12 mo	(33%) 48 mo
Alemtuzumab, IV		Pretreated	45	74	60	14	(26%) 12 mo	(18%) 48 mo
FMC + alemtuzumab, IV	Multicenter, prospective	Untreated	16	92	48	44	11.5	17.1	5
		Pretreated	9
Bendamustine	Multicenter, retrospective	Untreated	6	55.3	20	33.3	5	8.7	7
		Pretreated	9
Alemtuzumab, IV	Single center, retrospective	Untreated	42	81	61	20	11	15	15
Alemtuzumab, IV + pentostatin		Untreated	13	82	73	9	4.3	10.4
Alemtuzumab, IV		Pretreated	15	46	46	—	3	15
Alemtuzumab, IV + pentostatin		Pretreated	5	75	50	25	2.6	2.6
FMC + alemtuzumab, sc	Multicenter, prospective	Untreated	13	68.7	25.8% CR, 6.25% CRi	36.6	7.5	11.5	8
		Pretreated	5

sc, subcutaneous.